Observations, lessons, and takeaways from Monday’s failure of Gilead Sciences’ (GILD) NASH drug, selonsertib.
1. In defense of Gilead, a broad swath of Wall Street’s covering analysts argued the negative outcome of the Phase 3 study was expected and therefore already baked into the biotech’s diminished stock price.
But if everyone knew selonsertib was a zero — based on mediocre data culled from mid-stage studies — Gilead’s decision to forge ahead anyway with large and expensive late-stage clinical trials looks desperate and amateurish.
About the Author Reprints
cnat future results?
Seems CBAY has been forgotten about in the NASH market, maybe it is a prove it story, but seems worth keeping an eye on since other assets are struggling